Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Submitted by admin on March 17, 2025 - 10:14pm
Source: 
Investors Business Daily
News Tags: 
Incyte
povorcitinib
clinical trials
hidradenitis suppurativa
Headline: 
Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'
snippet: 

Incyte's (INCY) experimental skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed on disappointing study results.

Do Not Allow Advertisers to Use My Personal information